ANTIMURINE IL-6 RECEPTOR ANTIBODY INHIBITS IL-6 EFFECTS INVIVO

被引：12

作者：

SUZUKI, H

YASUKAWA, K

SAITO, T

ANZAI, M

GOITSUKA, R

HASEGAWA, A

OHSUGI, Y

TAGA, T

KISHIMOTO, T

机构：

[1] OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADAOKA,SUITA,OSAKA 565,JAPAN

[2] TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA,JAPAN

[3] UNIV TOKYO,FAC AGR,DEPT VET INTERNAL MED,TOKYO 113,JAPAN

[4] CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,SHIZUOKA,JAPAN

来源：

IMMUNOLOGY LETTERS | 1991年 / 30卷 / 01期

关键词：

IL-6; ANTIBODY; RECEPTOR; PLATELET; DNP;

D O I：

10.1016/0165-2478(91)90083-M

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Thrombopoiesis, as well as antibody production, is one of the major events in which interleukin-6 (IL-6) has been reported to be involved. Polyclonal antimurine IL-6 receptor antibody was prepared to examine the effect of the antibody on these events in IL-6-treated mice. Administration of the anti-mIL-6R antibody inhibited the IL-6-induced increase in the number of platelets. Enhancement of the serum level of DNP-specific antibody by intraperitoneal injection of IL-6 was inhibited completely with simultaneous administration of the anti-mIL-6R antibody. The level of DNP-specific antibody was decreased, even below the basal value, by the higher dose of anti-mIL-6R antibody, indicating its effect also on endogenous IL-6. This work provides evidence that anti-IL-6R antibody inhibits IL-6 function in vivo, and provides an animal model of the therapeutic use of anti-IL-6R antibody for IL-6-related disease.

引用

页码：17 / 22

页数：6

共 16 条

[1]

ASANO S, 1990, BLOOD, V75, P1602

[2] BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6 [J].

HIRANO, T ;

AKIRA, S ;

TAGA, T ;

KISHIMOTO, T .

IMMUNOLOGY TODAY, 1990, 11 (12) :443-449

[3] PURIFICATION TO HOMOGENEITY AND CHARACTERIZATION OF HUMAN B-CELL DIFFERENTIATION FACTOR (BCDF OR BSFP-2) [J].

HIRANO, T ;

TAGA, T ;

NAKANO, N ;

YASUKAWA, K ;

KASHIWAMURA, S ;

SHIMIZU, K ;

NAKAJIMA, K ;

PYUN, KH ;

KISHIMOTO, T .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (16) :5490-5494

[4]

HIRATA Y, 1989, J IMMUNOL, V143, P2900

[5] DIFFERENTIATION OF A CELL LINE OF MYELOID LEUKEMIA [J].

ICHIKAWA, Y .

JOURNAL OF CELLULAR PHYSIOLOGY, 1969, 74 (03) :223-&

[6]

ISHIBASHI T, 1989, BLOOD, V74, P1241

[7] AUTOCRINE GENERATION AND REQUIREMENT OF BSF-2/IL-6 FOR HUMAN MULTIPLE MYELOMAS [J].

KAWANO, M ;

HIRANO, T ;

MATSUDA, T ;

TAGA, T ;

HORII, Y ;

IWATO, K ;

ASAOKU, H ;

TANG, B ;

TANABE, O ;

TANAKA, H ;

KURAMOTO, A ;

KISHIMOTO, T .

NATURE, 1988, 332 (6159) :83-85

[8]

Klein B, 1990, Eur Cytokine Netw, V1, P193

[9] AIDS KAPOSI SARCOMA-DERIVED CELLS PRODUCE AND RESPOND TO INTERLEUKIN-6 [J].

MILES, SA ;

REZAI, AR ;

SALAZARGONZALEZ, JF ;

VANDERMEYDEN, M ;

STEVENS, RH ;

LOGAN, DM ;

MITSUYASU, RT ;

TAGA, T ;

HIRANO, T ;

KISHIMOTO, T ;

MARTINEZMAZA, O .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (11) :4068-4072

[10] RECOMBINANT HUMAN INTERLEUKIN-6 (B-CELL STIMULATORY FACTOR-II) IS A POTENT INDUCER OF DIFFERENTIATION OF MOUSE MYELOID-LEUKEMIA CELLS (M1) [J].

MIYAURA, C ;

ONOZAKI, K ;

AKIYAMA, Y ;

TANIYAMA, T ;

HIRANO, T ;

KISHIMOTO, T ;

SUDA, T .

FEBS LETTERS, 1988, 234 (01) :17-21

← 1 2 →